GlobalData on MSN21h
GSK gains approval in Japan for extended indication of RSV vaccine
GlaxoSmithKline (GSK) has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for its regulatory ...
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in ...
FiercePharma27d
GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes
For the company’s closely watched respiratory syncytial virus (RSV) vaccine Arexvy, those challenges led to drastically reduced sales. After a stunning ascension to blockbuster status in its RSV ...
Business Insider4d
GSK announces Japan’s MHLW approved application to extend indication of Arexvy
GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to include ...
Pharmabiz3d
Japan’s MHLW grants expanded indication approval to GSK’s RSV vaccine, Arexvy for adults aged 50-59 at increased risk of severe RSV disease
GSK plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a regulatory application to extend the indication of Arexvy (respiratory syncytial virus vaccine, recombinant ...
BioSpace6d
UK Patent Win Over GSK Boosts Pfizer in Global RSV Vaccine Fight
A judge in the U.K. last month sided with Pfizer over GSK in a respiratory syncytial virus vaccine patent lawsuit, ...
Business Insider4d
GSK Plc Announces Regulatory Expansion For Arexvy In Japan To Include Adults Aged 50-59
(RTTNews) - GSK plc (GSK, GSK.L) announced that Japan's Ministry of Health, Labour and Welfare has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV ...
London South East4d
GSK's Arexvy approved for wider age range in Japan
(Sharecast News) - Biopharma giant GSK has announced that Japanese regulators have expanded the approved use of its Arexvy vaccine for severe respiratory syncytial virus (RSV) disease to a wider ...
devdiscourse3d
Global Health Crises and Innovations: From Tainted Alcohol Tragedies to New Medical Advances
The latest health news includes the tragic death of two Australians from methanol poisoning in Laos, approval of GSK's RSV ...
Seeking Alpha1mon
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...
Reuters4d
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
GSK's RSV vaccine Arexvy has been approved in Japan for adults aged 60 and over since September last year for the prevention of the disease caused by RSV, a common contagious virus that affects ...
Yahoo Finance3d
GSK announces Japan’s MHLW approved application to extend indication of Arexvy
GSK (GSK) announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved a regulatory application to extend the indication of Arexvy for the prevention of RSV disease to ...